ContributorsPublishersAdvertisers

Olaparib Plus Pembrolizumab Demonstrates Manageable AEs in Advanced Cholangiocarcinoma

onclive.com
 2022-01-22

The combination of olaparib and pembrolizumab demonstrated acceptable safety and an manageable adverse effect profile in patients with advanced cholangiocarcinoma who had received prior gemcitabine-based therapy, according to findings from a phase 2 trial. The combination of olaparib (Lynparza) and pembrolizumab (Keytruda) demonstrated acceptable safety and an manageable adverse...

www.onclive.com

Comments / 0

Comments / 0